Is TFX a good stock to buy right now?

Based on our 6-factor quantitative model, TELEFLEX INC (TFX) receives a "Hold" rating with a composite score of 42.9/100. It is ranked #1,558 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 43/100, Momentum 36/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for TFX?

TELEFLEX INC (TFX) has a "Hold" rating and 3-star score. The composite score of 42.9 ranks it #1,558 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is TFX in?

TELEFLEX INC operates in the Healthcare sector (Medical Equipment industry) with a market cap of $5.23 billion. It is classified as a mid-cap stock.

Does TFX pay a dividend?

Yes, TFX pays a dividend with a current yield of 1.13%. For every $1,000 invested, you would receive approximately $11.30 in annual dividend income.

What is TFX's P/E ratio?

P/E ratio data is not currently available for TFX, which may indicate the company is not yet profitable.

How profitable is TFX?

TFX's quality factor score is 50/100. Gross margin: 57.4%. ROE: -2.6% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is TFX valued compared to peers?

TFX's value factor score is 43/100 (higher = cheaper). Key multiples: , EV/EBITDA 16.7x. Valuation is roughly in line with peers.

What is TFX's debt level?

TFX's debt-to-equity ratio is 85%. Sector average: 32%. Moderate leverage is normal for established companies.

TFX has a beta of 0.74, meaning it is less volatile than the market. Stability score: 66/100.

Does TFX have high short interest?

TFX's short interest factor score is 22/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

TFX Stock Analysis: Top Mid-Cap Hold (Score 42.9/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
TFX	-1.56%	+0.49%	+5.86%	-2.99%	-8.27%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-1.50%	-3.11%	+5.52%	-2.63%	-37.80%	-	-	-
Alpha vs Sector	-0.21%	+0.15%	+9.67%	+1.85%	-17.48%	-	-	-

Metric	TFX	Benchmark
P/E Ratio	-63.4x	-368%
EV/EBITDA	16.7x	+163%
Price / Book	1.6x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
TFX TELEFLEX INC	43	50	43	36	-	-2.6%	57.4%	-1.7%	-24.4%	85.0x	$5.2B

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.6%	0.6%	0.6%	0.6%	0.5%	0.6%	0.5%	0.5%	0.5%	0.5%	0.5%
Operating Margin %	0.1%	0.1%	0.0%	0.2%	0.2%	0.2%	0.2%	0.2%	0.1%	0.2%	0.2%
EBITDA Margin %	0.2%	0.1%	0.1%	0.3%	0.3%	0.3%	0.3%	0.2%	0.2%	0.2%	0.2%
Net Margin %	-0.0%	-0.5%	0.0%	0.1%	0.1%	0.2%	0.1%	0.2%	0.1%	0.1%	0.1%
FCF Margin %	-19.4%	-	-	-	-	-	13.7%	12.9%	14.5%	16.6%	19.0%
ROE %	-0.0%	-0.3%	0.0%	0.1%	0.1%	0.1%	0.1%	0.2%	0.1%	0.1%	0.1%
ROA %	-0.0%	-0.1%	0.0%	0.0%	0.1%	0.1%	0.0%	0.1%	0.0%	0.0%	0.1%
ROIC %	0.1%	1.6%	2.0%	6.4%	6.9%	8.9%	6.0%	7.1%	5.7%	6.7%	9.6%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.6%

0.5%

0.6%

0.5%

Operating Margin %

0.1%

0.0%

0.2%

0.1%

0.2%

EBITDA Margin %

0.2%

0.1%

0.3%

0.2%

Net Margin %

-0.0%

-0.5%

0.0%

0.1%

0.2%

0.1%

0.2%

0.1%

FCF Margin %

-19.4%

13.7%

12.9%

14.5%

16.6%

19.0%

ROE %

-0.0%

-0.3%

0.0%

0.1%

0.2%

0.1%

ROA %

-0.0%

-0.1%

0.0%

0.1%

0.0%

0.1%

0.0%

0.1%

ROIC %

0.1%

1.6%

2.0%

6.4%

6.9%

8.9%

6.0%

7.1%

5.7%

6.7%

9.6%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$2.2B	$2.0B	$3.0B	$3.0B	$2.8B	$2.8B	$2.5B	$2.6B	$2.4B	$2.1B	$1.9B	$1.8B
	—	$872M	$1.3B	$1.3B	$1.3B	$1.3B	—	—	—	—	—	—
	$1.2B	$1.1B	$1.7B	$1.6B	$1.5B	$1.5B	$1.3B	$1.5B	$1.4B	$1.2B	$996M	$944M
Gross Margin	57.4%	56.2%	55.9%	55.4%	54.9%	55.1%	52.2%	54.3%	53.2%	54.6%	53.3%	52.2%
	—	$720M	$995M	$930M	$864M	$860M	—	—	—	—	—	—
Research & Development	—	$145M	$162M	$154M	$154M	$131M	$120M	$114M	$106M	$85M	$59M	$52M
Depreciation	—	$178M	$275M	$242M	$231M	$237M	$232M	$218M	$215M	$160M	$128M	$125M
Total Operating Expenses	—	$1.0B	$1.6B	$1.1B	$1.0B	$922M	—	—	—	—	—	—
	$254M	$118M	$151M	$506M	$500M	$628M	$423M	$427M	$322M	$372M	$319M	$316M
EBIT	$254M	$118M	$151M	$506M	$500M	$628M	$423M	$427M	$322M	$372M	$319M	$316M
EBITDA	$465M	$296M	$426M	$748M	$730M	$865M	$655M	$646M	$536M	$533M	$448M	$441M
Operating Margin	11.9%	5.9%	5.0%	17.0%	17.9%	22.4%	16.7%	16.5%	13.1%	17.3%	17.1%	17.5%
EBITDA Margin	21.2%	14.9%	14.0%	25.2%	26.2%	30.8%	25.8%	24.9%	21.9%	24.8%	24.0%	24.4%
	—	—	—	$85M	$54M	$57M	$66M	$89M	$103M	$88M	$74M	$72M
	—	$25M	$75M	$434M	$446M	$559M	—	—	—	—	—	—
Income Tax Expense	—	-$34M	$5M	$76M	$83M	$74M	$22M	-$122M	$23M	$130M	$8M	$8M
	-$80M	-$906M	$70M	$356M	$363M	$485M	$335M	$461M	$201M	$153M	$238M	$246M
Net Margin	-1.7%	-45.5%	2.3%	12.0%	13.0%	17.3%	13.2%	17.8%	8.2%	7.1%	12.7%	13.6%
	$-20.30	$-20.30	$1.49	$7.58	$7.74	$10.38	$7.21	$9.99	$4.39	$3.39	$5.48	$5.89
Diluted EPS	$-20.30	$-20.25	$1.48	$7.53	$7.68	$10.23	$7.21	$9.99	$4.39	$3.39	$5.48	$5.89
Weighted Avg Basic	—	45M	47M	47M	47M	47M	—	—	—	—	—	—
Weighted Avg Diluted	—	45M	47M	47M	47M	47M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$2.2B

$2.0B

$3.0B

$2.8B

$2.5B

$2.6B

$2.4B

$2.1B

$1.9B

$1.8B

—

$872M

$1.3B

—

$1.2B

$1.1B

$1.7B

$1.6B

$1.5B

$1.3B

$1.5B

$1.4B

$1.2B

$996M

$944M

Gross Margin

57.4%

56.2%

55.9%

55.4%

54.9%

55.1%

52.2%

54.3%

53.2%

54.6%

53.3%

52.2%

—

$720M

$995M

$930M

$864M

$860M

—

Research & Development

—

$145M

$162M

$154M

$131M

$120M

$114M

$106M

$85M

$59M

$52M

Depreciation

—

$178M

$275M

$242M

$231M

$237M

$232M

$218M

$215M

$160M

$128M

$125M

Total Operating Expenses

—

$1.0B

$1.6B

$1.1B

$1.0B

$922M

—

$254M

$118M

$151M

$506M

$500M

$628M

$423M

$427M

$322M

$372M

$319M

$316M

EBIT

$254M

$118M

$151M

$506M

$500M

$628M

$423M

$427M

$322M

$372M

$319M

$316M

EBITDA

$465M

$296M

$426M

$748M

$730M

$865M

$655M

$646M

$536M

$533M

$448M

$441M

Operating Margin

11.9%

5.9%

5.0%

17.0%

17.9%

22.4%

16.7%

16.5%

13.1%

17.3%

17.1%

17.5%

EBITDA Margin

21.2%

14.9%

14.0%

25.2%

26.2%

30.8%

25.8%

24.9%

21.9%

24.8%

24.0%

24.4%

—

$85M

$54M

$57M

$66M

$89M

$103M

$88M

$74M

$72M

—

$25M

$75M

$434M

$446M

$559M

—

Income Tax Expense

—

-$34M

$5M

$76M

$83M

$74M

$22M

-$122M

$23M

$130M

$8M

-$80M

-$906M

$70M

$356M

$363M

$485M

$335M

$461M

$201M

$153M

$238M

$246M

Net Margin

-1.7%

-45.5%

2.3%

12.0%

13.0%

17.3%

13.2%

17.8%

8.2%

7.1%

12.7%

13.6%

$-20.30

$1.49

$7.58

$7.74

$10.38

$7.21

$9.99

$4.39

$3.39

$5.48

$5.89

Diluted EPS

$-20.30

$-20.25

$1.48

$7.53

$7.68

$10.23

$7.21

$9.99

$4.39

$3.39

$5.48

$5.89

Weighted Avg Basic

—

45M

47M

—

Weighted Avg Diluted

—

45M

47M

—

TELEFLEX INC (TFX) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does TELEFLEX INC Do?

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania. TELEFLEX INC (TFX) is classified as a mid-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Liam J. Kelly and employs approximately 15,500 people, headquartered in Wayne, Pennsylvania. With a market capitalization of $5.2B, TFX is one of the notable companies in the Healthcare sector.

TELEFLEX INC (TFX) Stock Rating — Hold (April 2026)

As of April 2026, TELEFLEX INC receives a Hold rating with a composite score of 42.9/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.TFX ranks #1,558 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, TELEFLEX INC ranks #134 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TFX Stock Price and 52-Week Range

TELEFLEX INC (TFX) currently trades at $118.39. The stock lost $1.88 (1.6%) in the most recent trading session. The 52-week high for TFX is $143.31, which means the stock is currently trading -17.4% from its annual peak. The 52-week low is $100.18, putting the stock 18.2% above its annual trough. Recent trading volume was 476K shares, suggesting relatively thin trading activity.

Is TFX Overvalued or Undervalued? — Valuation Analysis

TELEFLEX INC (TFX) carries a value factor score of 43/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The price-to-book ratio stands at 1.63x, versus the sector average of 2.75x. The price-to-sales ratio is 2.33x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, TFX trades at 16.67x EV/EBITDA, versus 6.34x for the sector.

Overall, TFX's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

TELEFLEX INC Profitability — ROE, Margins, and Quality Score

TELEFLEX INC (TFX) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is -2.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -1.2% versus the sector average of -33.1%.

On a margin basis, TELEFLEX INC reports gross margins of 57.4%, compared to 71.5% for the sector. The operating margin is 11.9% (sector: -66.1%). Net profit margin stands at -1.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -24.4% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

TFX Debt, Balance Sheet, and Financial Health

TELEFLEX INC has a debt-to-equity ratio of 85.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.54x, indicating strong short-term liquidity. Total debt on the balance sheet is $2.64B. Cash and equivalents stand at $354M.

TFX has a beta of 0.74, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for TELEFLEX INC is 66/100, reflecting average volatility within the normal range for its sector.

TELEFLEX INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, TELEFLEX INC reported revenue of $2.19B and earnings per share (EPS) of $-20.30. Net income for the quarter was $-80M. Gross margin was 57.4%. Operating income came in at $254M.

In FY 2025, TELEFLEX INC reported revenue of $1.99B and earnings per share (EPS) of $-20.30. Net income for the quarter was $-906M. Gross margin was 56.2%. Revenue grew -34.6% year-over-year compared to FY 2024. Operating income came in at $118M.

In Q3 2025, TELEFLEX INC reported revenue of $567M and earnings per share (EPS) of $-9.24. Net income for the quarter was $-409M. Gross margin was 51.5%. Revenue grew -25.8% year-over-year compared to Q3 2024. Operating income came in at $-62M.

In Q2 2025, TELEFLEX INC reported revenue of $443M and earnings per share (EPS) of $2.77. Net income for the quarter was $123M. Gross margin was 60.1%. Revenue grew -41.0% year-over-year compared to Q2 2024. Operating income came in at $91M.

Over the past 8 quarters, TELEFLEX INC has demonstrated a growth trajectory, with revenue expanding from $750M to $2.19B. Investors analyzing TFX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TFX Dividend Yield and Income Analysis

TELEFLEX INC (TFX) currently pays a dividend yield of 1.1%. At this yield, a $10,000 investment in TFX stock would generate approximately $$113.00 in annual dividend income.

TFX Momentum and Technical Analysis Profile

TELEFLEX INC (TFX) has a momentum factor score of 36/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 38/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 22/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

TFX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, TELEFLEX INC (TFX) ranks #134 out of 838 stocks based on the Blank Capital composite score. This places TFX in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TFX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TFX vs S&P 500 (SPY) comparison to assess how TELEFLEX INC stacks up against the broader market across all factor dimensions.

TFX Next Earnings Date

No upcoming earnings date has been announced for TELEFLEX INC (TFX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TFX? — Investment Thesis Summary

TELEFLEX INC presents a balanced picture with arguments on both sides. Momentum is weak at 36/100, a headwind for near-term performance. Low volatility (stability score 66/100) reduces downside risk.

In summary, TELEFLEX INC (TFX) earns a Hold rating with a composite score of 42.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TFX stock.

Related Resources for TFX Investors

Explore more research and tools: TFX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TFX head-to-head with peers: TFX vs AZN, TFX vs SLGL, TFX vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Is Teleflex’s Governance Overhaul And Capital Moves Altering The Investment Case For TFX?

Does Teleflex’s Governance Shakeup And Early Buybacks Shift The Bull Case For TFX?

Is Teleflex (TFX) Pricing Look Attractive After Recent Share Price Weakness

Does Teleflex (TFX) have the Potential to become a High-Growth Business?

Assessing Teleflex (TFX) Valuation As Mixed Share Price Momentum Draws Fresh Investor Attention

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

TELEFLEX INC (TFX) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does TELEFLEX INC Do?

TELEFLEX INC (TFX) Stock Rating — Hold (April 2026)

TFX Stock Price and 52-Week Range

Is TFX Overvalued or Undervalued? — Valuation Analysis

TELEFLEX INC Profitability — ROE, Margins, and Quality Score

TFX Debt, Balance Sheet, and Financial Health

TELEFLEX INC Revenue and Earnings History — Quarterly Trend

TFX Dividend Yield and Income Analysis

TFX Momentum and Technical Analysis Profile

TFX vs Competitors — Healthcare Sector Ranking and Peer Comparison

TFX Next Earnings Date

Should You Buy TFX? — Investment Thesis Summary

Related Resources for TFX Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Is Teleflex’s Governance Overhaul And Capital Moves Altering The Investment Case For TFX?

Does Teleflex’s Governance Shakeup And Early Buybacks Shift The Bull Case For TFX?

Is Teleflex (TFX) Pricing Look Attractive After Recent Share Price Weakness

Does Teleflex (TFX) have the Potential to become a High-Growth Business?

Assessing Teleflex (TFX) Valuation As Mixed Share Price Momentum Draws Fresh Investor Attention